Source: Switzerland Global Enterprise
Publication Date: November 30, 2015
PaxVax, founded in 2007, is an American specialty vaccine company with its headquarters in Redwood City, California. In 2014 the life sciences firm acquired PaxVax Berna in Thörishaus in the Canton of Bern. As a result of this purchase the company more than doubled its size and commercialized its first product (the oral typhoid vaccine Vivotif®). The CEO and President of PaxVax, Nima Farzan, was delighted about how great Switzerland presents itself for growing a company. The local workforce is extraordinary, he adds: «They have excellent technical skills. Some of the Swiss experts were even sent to San Diego to share their knowledge and experience with their American colleagues.» Moreover, the favorable regulatory environment, labor and tax laws as well as the strong support from the Swiss authorities has contributed to a positive business environment for PaxVax. A further advantage of Switzerland as a business location is the proximity to numerous international organizations. For instance, PaxVax Berna is located close to the World Health Organization (WHO) which provides ease of access to an important stakeholder. According to Farzan, who was the former Vice President of Marketing for Novartis Vaccines USA, Switzerland is one of the two leading markets for life sciences after the US.